Diarrhea Predominant Irritable Bowel Syndrome in Females
NCT00461526 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 240
Last updated 2019-11-25
Summary
Clinical Trial with TRN-002 in Women with Irritable Bowel Syndrome (IBS)
The purpose of this study is to investigate the safety and effectiveness of a new investigational drug in women for the treatment of diarrhea-predominant irritable bowel syndrome. The investigational drug is a natural product taken from a plant that grows in South America. The study medication will be administered orally twice a day. Subjects will be not able to remain on certain standard IBS medications (anti-diarrheals) while participating in the study. The total duration of the study is 18 weeks.
The study requires five study visits that include physical exams, ECG, blood draws, laboratory studies, and a colon procedure (such as a colonoscopy or flexible sigmoidoscopy if an appropriate procedure has not been performed in the last 5 years.) Participants will be asked to make entries into a touch-tone telephone diary on a daily basis.
Participants must meet all of the following criteria:
* Females at least 18 years of age
* Diagnosis of diarrhea predominant Irritable Bowel Syndrome
* Willingness to make daily calls on a touch-tone telephone
* Willingness to have an endoscopic and/or radiologic bowel evaluation, if you have not received one in the past 5 years.
* Willingness to take an approved method of birth control (if required)
Participants CANNOT meet any of the following criteria:
* Serious medical or surgical conditions
* Colon Cancer, Crohns Disease or Ulcerative Colitis
* Pregnant or breast feeding
Conditions
- Irritable Bowel Syndrome
Interventions
- DRUG
-
crofelemer
125 mg crofelemer vs. placebo
Sponsors & Collaborators
-
Bausch Health Americas, Inc.
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-10-31
- Primary Completion
- 2007-12-31
- Completion
- 2007-12-31
Countries
- United States
Study Locations
More Related Trials
-
Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor Functions in Patients With Irritable Bowel Syndrome (IBS)
NCT01253408 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
NCT01887002 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Evaluate Efficacy of Ramosetron on Diarrhea-predominant Irritable Bowel Syndrome (IBS) in Male Patients
NCT01225237 ·Status: COMPLETED ·Phase: PHASE4
-
Effects Of GW876008 On The Bowel In Patients With Irritable Bowel Syndrome
NCT00385099 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 1, Randomized, Placebo-Controlled, Ascending Cohort, Dose Escalation Study in Normal Healthy Volunteers
NCT02727283 ·Status: COMPLETED ·Phase: PHASE1
-
Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS)
NCT00101985 ·Status: COMPLETED ·Phase: PHASE2
-
Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).
NCT06153420 ·Status: TERMINATED ·Phase: PHASE2
-
Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)
NCT00394173 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)
NCT01340053 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of 3 Doses of Dextofisopam in Females With Irritable Bowel Syndrome
NCT00486876 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Safety and Effectiveness of DDP733 in Treating IBS With Constipation in Females
NCT00547469 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)
NCT02493452 ·Status: COMPLETED ·Phase: PHASE3
-
8 Weeks Treatment With DDP225 in Patients With Diarrhea Predominant IBS
NCT00230581 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Ranolazine on Gastrointestinal Motor Function and Pain in Patients With IBS-D
NCT02239926 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome
NCT01736423 ·Status: COMPLETED ·Phase: PHASE3
-
Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
NCT00607971 ·Status: TERMINATED ·Phase: PHASE3
-
The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)
NCT01923428 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)
NCT02387359 ·Status: COMPLETED ·Phase: PHASE3
-
12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
NCT02107196 ·Status: COMPLETED ·Phase: PHASE3
-
IQP-CL-101 in IBS Management
NCT01774825 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Efficacy of YM060 on Diarrhea-predominant Irritable Bowel Syndrome (D-IBS) in Female Patients
NCT01274000 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of BMS-562086 in Patients With Irritable Bowel Syndrome
NCT00399438 ·Status: COMPLETED ·Phase: PHASE2
-
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
NCT02120027 ·Status: TERMINATED ·Phase: PHASE3
-
The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)
NCT01722318 ·Status: COMPLETED ·Phase: PHASE2
-
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
NCT01543178 ·Status: COMPLETED ·Phase: PHASE3